Literature DB >> 21304083

Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants.

Christine E Jones1, Shalena Naidoo, Corena De Beer, Monika Esser, Beate Kampmann, Anneke C Hesseling.   

Abstract

CONTEXT: Altered immune responses might contribute to the high morbidity and mortality observed in human immunodeficiency virus (HIV)-exposed uninfected infants.
OBJECTIVE: To study the association of maternal HIV infection with maternal- and infant-specific antibody levels to Haemophilus influenzae type b (Hib), pneumococcus, Bordetella pertussis antigens, tetanus toxoid, and hepatitis B surface antigen. DESIGN, SETTING, AND PARTICIPANTS: A community-based cohort study in Khayelitsha, Western Cape Province, South Africa, between March 3, 2009, and April 28, 2010, of 109 HIV-infected and uninfected women and their infants. Serum samples from 104 women and 100 infants were collected at birth and samples from 93 infants were collected at 16 weeks. MAIN OUTCOME MEASURE: Level of specific antibody in mother-infant pairs at delivery and in infants at 16 weeks, determined by enzyme-linked immunosorbent assays.
RESULTS: At birth, HIV-exposed uninfected infants (n = 46) had lower levels of specific antibodies than unexposed infants (n = 54) did to Hib (0.37 [interquartile range {IQR}, 0.22-0.67] mg/L vs 1.02 [IQR, 0.34-3.79] mg/L; P < .001), pertussis (16.07 [IQR, 8.87-30.43] Food and Drug Administration [FDA] U/mL vs 36.11 [IQR, 20.41-76.28] FDA U/mL; P < .001), pneumococcus (17.24 [IQR, 11.33-40.25] mg/L vs 31.97 [IQR, 18.58-61.80] mg/L; P = .02), and tetanus (0.08 [IQR, 0.03-0.39] IU/mL vs 0.24 [IQR, 0.08-0.92] IU/mL; P = .006). Compared with HIV-uninfected women (n = 58), HIV-infected women (n = 46) had lower specific antibody levels to Hib (0.67 [IQR, 0.16-1.54] mg/L vs 1.34 [IQR, 0.15-4.82] mg/L; P = .009) and pneumococcus (33.47 [IQR, 4.03-69.43] mg/L vs 50.84 [IQR, 7.40-118.00] mg/L; P = .03); however, no differences were observed for antipertussis or antitetanus antibodies. HIV-exposed uninfected infants (n = 38) compared with HIV-unexposed infants (n = 55) had robust antibody responses following vaccination, with higher antibody responses to pertussis (270.1 [IQR, 84.4-355.0] FDA U/mL vs 91.7 [IQR, 27.9-168.4] FDA U/mL; P = .006) and pneumococcus (47.32 [IQR, 32.56-77.80] mg/L vs 14.77 [IQR, 11.06-41.08] mg/L; P = .001).
CONCLUSION: Among South African infants, antenatal HIV exposure was associated with lower specific antibody responses in exposed uninfected infants compared with unexposed infants at birth, but with robust responses following routine vaccination.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21304083     DOI: 10.1001/jama.2011.100

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  103 in total

1.  Do children exposed to human immunodeficiency virus but not infected actually have a more robust response to hepatitis B vaccination than their nonexposed peers?

Authors:  Olivia Swann; Ewen M Harrison
Journal:  Clin Vaccine Immunol       Date:  2012-02

2.  Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants.

Authors:  Soren Gantt; Jackson Orem; Elizabeth M Krantz; Rhoda Ashley Morrow; Stacy Selke; Meei-Li Huang; Joshua T Schiffer; Keith R Jerome; Annet Nakaganda; Anna Wald; Corey Casper; Lawrence Corey
Journal:  J Infect Dis       Date:  2016-02-24       Impact factor: 5.226

Review 3.  Impact of maternal HIV exposure, feeding status, and microbiome on infant cellular immunity.

Authors:  Sonwabile Dzanibe; Heather B Jaspan; Michael Z Zulu; Agano Kiravu; Clive M Gray
Journal:  J Leukoc Biol       Date:  2018-12-21       Impact factor: 4.962

4.  Influence of new antiretrovirals on hematological toxicity in HIV-exposed uninfected infants.

Authors:  Núria Rovira; Antoni Noguera-Julian; Susana Rives; Rubén Berrueco; Rebeca Lahoz; Clàudia Fortuny
Journal:  Eur J Pediatr       Date:  2016-05-10       Impact factor: 3.183

5.  Executive summary: 2013 update of the guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman
Journal:  Pediatr Infect Dis J       Date:  2013-12       Impact factor: 2.129

Review 6.  Tuberculosis susceptibility and protection in children.

Authors:  Robindra Basu Roy; Elizabeth Whittaker; James A Seddon; Beate Kampmann
Journal:  Lancet Infect Dis       Date:  2018-10-12       Impact factor: 25.071

Review 7.  The Immune System of HIV-Exposed Uninfected Infants.

Authors:  Bahaa Abu-Raya; Tobias R Kollmann; Arnaud Marchant; Duncan M MacGillivray
Journal:  Front Immunol       Date:  2016-09-28       Impact factor: 7.561

8.  Bridging the gap: maternal immunisation as a means to reduce neonatal deaths from infectious diseases.

Authors:  Ben Lindsey; Christine Jones; Beate Kampmann
Journal:  Pathog Glob Health       Date:  2012-07       Impact factor: 2.894

Review 9.  HIV-exposed uninfected children: a growing population with a vulnerable immune system?

Authors:  L Afran; M Garcia Knight; E Nduati; B C Urban; R S Heyderman; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

10.  Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.

Authors:  Myron J Levin; Jane C Lindsey; Susan S Kaplan; Werner Schimana; Jody Lawrence; Monica M McNeal; Mutsa Bwakura-Dangarembizi; Anthony Ogwu; Evans M Mpabalwani; Paul Sato; George Siberry; Margaret Nelson; Darcy Hille; Geoffrey A Weinberg; Adriana Weinberg
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.